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ABSTRACT
Tensin family members, including tensin2 (TNS2), are present as major 
components of the focal adhesions. The N-terminal end of TNS2 contains a C1 region 
(protein kinase C conserved region 1) that is not found in other tensin members. 
Three isoforms of TNS2 have been identified with previous reports describing the 
shortest V3 isoform as lacking the C1 region. Although TNS2 is known to regulate 
cell proliferation and migration, its role in tumorigenicity is controversial. By gain-of-
function overexpression approaches, results supporting either promotion or reduction 
of cancer cell tumorigenicity were reported. Here we report that the complete V3 
isoform also contains the C1 region and describe the expression patterns of the three 
human TNS2 isoforms. By loss-of-function approaches, we show that silencing of TNS2 
up-regulates the activities of Akt, Mek, and IRS1, and increases tumorigenicities in 
A549 and Hela cells. Using public database analyses we found that TNS2 is down-
regulated in head and neck, esophageal, breast, lung, liver, and colon cancer. In 
addition, patients with low TNS2 expression showed poor relapse-free survival 
rates for breast and lung cancers. These results strongly suggest a role of tensin2 in 
suppressing cell transformation and reduction of tumorigenicity.
INTRODUCTION
Focal adhesions are transmembrane junctions 
linking the extracellular matrix to the cytoskeletons. 
They are critical structures in organizing the cytoskeleton 
network and transmitting signals that regulate cell 
adhesion, migration, proliferation, differentiation, and 
tissue development [1]. When the functions of focal 
adhesions go awry, they may lead to disease formation 
[1]. Tensin2 (TNS2) is a member of the tensin family that 
includes tensin1, tensin3, and cten [2]. All four tensin 
proteins localize to focal adhesions and contain the PTP 
(protein tyrosine phosphatase), SH2 (Src homology 2), 
and PTB (phosphotyrosine binding) domains, except that 
cten is shorter and does not share the PTP domain [2]. 
In addition, TNS2 features a C1 region (protein kinase 
C conserved region 1) that is not found in other tensin 
members. TNS2 is reported to regulate cell proliferation 
and migration [3, 4] and to be critical for cell to contract 
collagen gels [5]. The role of TNS2 in tumorigenesis is 
somewhat confusing. Over-expression of one tensin2 
variant (V2, 1409aa) in BEL7402 and HepG2 reduced 
their colony formation activities [6]. On the other hand, 
over-expression of another TNS2 variant lacking the C1 
region (1285aa) promoted BEL7402 cell proliferation, 
migration, and colony formation, as well as tumor growth 
in orthotopic liver xenograft [7]. In low serum condition, 
HEK293 cells transfected with TNS2 (V2, 1409aa) 
proliferated slower than control cells [3]. Whether these 
discrepancies are caused by different cell types and/or 
TNS2 variants are not clear.
The TNS2 knockout mice have not yet been 
reported. However, the role of TNS2 in mice has been 
suggested by an ICR-derived glomerulonephritis (ICGN) 
mouse model. TNS2 harboring an 8-nucleotide deletion 
that led to its early termination was believed to be the 
cause of the congenital nephrotic syndrome in the ICGN 
mice [8]. It was shown that the number of glomerular 
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podocytes was significantly reduced, which might result 
in proteinuria that induced chronic kidney disease in the 
ICGN mice [9]. However, the phenotype of ICGN is 
dictated by mouse genetic backgrounds. By backcrossing 
and tracking the TNS2 mutant allele, renal phenotypes 
were only detected in homozygous TNS2 mutant mice in 
the BDA/2J or FBV/N strains [10, 11] but not in C57BL 
or SV129 mice [12]. A genome-wide linkage analysis 
using C57BL and ICGN backcross mice carrying TNS2 
mutations has suggested significant chronic kidney disease 
resistance loci on mouse chromosome 2 and 13 [13]. The 
genetic modifiers and molecular mechanisms leading to 
the renal phenotypes remain to be established.
In this study, we have clarified the identities of three 
human TNS2 isoforms and established the loss-of-function 
effects of TNS2 in cancer cells. These three TNS2 isoforms 
only differ at their N-termini and these differences do not 
appear to alter their subcellular localization. Silencing of 
TNS2 promotes the activation of IRS1, Akt, and Mek, 
and enhances cancer cell tumorigenicities. Analysis of 
TNS2 expression patterns in human cancer patients has 
indicated that TNS2 is rarely overexpressed in cancers 
and patients with low TNS2 expression are associated 
with poor relapse-free survival probabilities in breast 
and lung cancers. These results demonstrate a role of 
TNS2 in suppressing cell transformation and reduction of 
tumorigenicity.
RESULTS
Three human TNS2 isoforms differ at their 
N-termini
Several TNS2 isoforms have been reported in 
various publications. Identification of human TNS2 was 
first reported in 2002 [4, 14] and it was also called C1-
ten because it contained a C1 domain at its N-terminal 
region [14], which was not found in other tensin members. 
Three isoforms named V1 (1419 aa), V2 (1409 aa), and 
V3 were described later [7, 15]. Both reports stated that 
V3 (derived from KIAA 1075) was the shortest form 
with no C1 domain. Nonetheless, with careful analysis of 
the KIAA1075 cDNA sequence, an open reading frame 
upstream of the proposed start codon was identified, with 
this region encoded identical amino acid sequence with 
those of V1 and V2 including the C1 domain. However, 
no start codon upstream of the C1 coding region was 
found in the original KIAA1075. Using 5’-RACE we 
tested whether a start codon upstream of the C1 coding 
region could be found. In addition to the sequences 
coding for the N-termini of V1 and V2, we also identified 
a new sequence with a start codon leading to a novel 
N-terminus (Figure 1A). With this new coding N-terminal 
sequence, this isoform would encode for a 1403 amino 
acid polypeptide. Given this data, it is very likely that 
the original KIAA1075 is an incomplete form of the 
TNS2 V3 isoform. Therefore, all three isoforms encode 
identical protein sequences except 35, 25, and 19 residues 
at the very N-terminal of V1, V2, and V3 respectively. 
Alignment with human genomic sequence allowed us to 
clarify the positions of exon 1a, 1b, and 1c that contained 
the unique sequences for V1, V2, and V3, and all three 
isoforms share the rest of exons (Figure 1B).
Expression profiles of TNS2 isoforms
Primers specific for each isoform were used for 
qPCR assay to establish the expression profiles in human 
tissues. Higher expression levels of TNS2 V1 and V3 were 
found in skeletal muscle, and V2 was in pancreas and heart 
(Figure 2A). Overall, V1 and V3 appeared to have similar 
tissue expression patterns that were different from V2. 
Interestingly, only one mouse TNS2 was found in NCBI 
reference sequence database. Based on its encoded amino 
acid sequence, mouse TNS2 is more related to human V2 
form (Figure 1A). The qPCR result showed that mouse 
TNS2 mRNA levels were higher in heart, kidney, skeletal 
muscle and aorta (Figure 2B).
Subcellular localization of TNS2 isoforms
To investigate the subcellular localization of these 
three isoforms, EGFP-tagged TNS2 constructs were 
transfected into HeLa cells. All three isoforms co-localized 
with vinculin at focal adhesion sites (Figure 3A). To 
further distinguish any potential difference in subcellular 
localization among these isoforms, we generated Tomato-
tagged TNS2 V1 and cotransfected with EGFP-tagged V2 
or V3 into HeLa cells. TNS2 V1, V2, and V3 isoforms 
had the same distribution at focal adhesions as well as 
the punctuate staining (Figure 3B) reported in several 
publications [15, 16]. These results indicated that the 
N-terminal variations in TNS2 isoforms had no detectable 
effect on their subcellular localization.
Silencing of TNS2 enhances tumorigenicity of 
cancer cell lines
A panel of human cancer cell lines was screened 
by immunoblot analysis to evaluate for TNS2 protein 
expression. While TNS2 protein was detected in A549, 
HCT116, SW480, SW620, DU145, and HeLa, no TNS2 
band was observed in H460, HCC827, Colo205, LS-180, 
PC3, HLE, Huh7, HepG2, Hep3B, and CL48 cell lysates 
(Figure 4A). To establish the functional roles of TNS2 
in cancer cells, TNS2 was down-regulated by the siRNA 
approach in HeLa and A549 cells. We selected HeLa due 
to its high TNS2 protein level and A549, the only TNS2-
positive lung cancer cell line we found, because of the 
clinical significance of TNS2 in lung cancer (see below). 
Although the siRNA targeted the common region shared 
by all three isoforms of TNS2, it appeared to be more 
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efficient in reducing the mRNA level of V1 form, also 
the dominant form, in A549 and HeLa cells (Figure 4B). 
Nonetheless, TNS2 protein levels were markedly down-
regulated by siRNA against TNS2 (siTNS2) in both cell 
lines (Figure 4C). Silencing of TNS2 promoted cancer 
cell proliferation and colony formation activities in both 
HeLa and A549 cells (Figure 4D&4E). For xenograft 
assays, a shRNA lentivirus targeting human TNS2 3’ UTR 
region was used for establishing TNS2 knockdown in 
HeLa cells. HeLa control (shLuc) and TNS2 knockdown 
(shTNS2) cells were injected into immune deficient NSG 
mice. shTNS2 HeLa cells developed significantly larger 
Figure 2: TNS2 expression patterns in humans and mice. A. Real-time qPCR analysis of TNS2 gene using three human isoform 
specific primers (described in M&M) in human tissues. B. TNS2 expression in mouse tissues. The relative mRNA values have been 
normalized to β-actin.
Figure 1: TNS2 has three isoforms in humans A. Alignment of the open reading frame encoded by three human isoforms and one 
mouse transcript. The N-terminal C1 regions and first 7 exons are shown. Identical residues are indicated with * asterisks. Arrow indicates 
the start site used in the KIAA1075 clone. B. Schematic overview of the 5’ end of the TNS2 gene. Exons and introns are depicted as boxes 
and lines, respectively. The independent splicing of alternative 5’ exons (1a, 1b, and 1c) generates three transcripts with different 5’ end 
sequences.
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tumors than shLuc cells (Figure 5), demonstrating a role 
of TNS2 in suppressing tumorigenicity. To establish the 
underlying mechanisms, we investigated the potential 
involvements of several signaling molecules. Silencing 
of TNS2 markedly increased the activated forms of IRS1 
(human pS616, pY612, or mouse pS612, pY608), Akt 
(pS473), Mek (pS217/221), and Erk (pT202/pY204), as 
well as IRS1 protein levels (Figure 6A), suggesting that 
TNS2 negatively regulated these pathways. To examine 
whether the increased IRS1 protein and phosphorylation 
levels were dependent on Mek and/or Akt pathways, TNS2 
knockdown cells were treated with inhibitors to Mek or 
PI3K (upstream of Akt). While Mek (U0126) and PI3K 
(LY294002) inhibitors suppressed IRS1 phosphorylation 
and protein levels induced by TNS2 knockdown in 
A549 cells, only U0126 significantly reduced IRS 
phosphorylation in HeLa cells (Figure 6B), suggesting that 
the Mek pathway is critical for enhancing IRS1 activation 
levels in TNS2 knockdown cells.
TNS2 is down-regulated in human cancers and 
low expression is associated with poor survival 
potential
To determine the clinical relevance of TNS2 
expression in cancer patients, we have searched and 
analyzed publicly available expression databases. Six 
expression datasets containing human normal and cancer 
Figure 3: Subcellular localization of TNS2 isoforms. A. HeLa cells were transfected with EGFP-TNS2 V1, V2, or V3 and 
stained with anti-vinculin antibodies. TNS2, vinculin, and nuclei are shown in green, red, and blue, respectively. B. Tomato-TNS2 V1 
was cotransfected with EGFP-TNS2 V2 or V3 into HeLa cells. TNS2 V2 or V3 are shown in green, while TNS2 V1 is in red. Arrows and 
arrowheads indicate focal adhesions and punctuate staining respectively
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paired (≥ 20) samples from GEO were found and analyzed. 
When compared to their paired adjacent normal samples, 
TNS2 mRNA was shown to be significantly downregulated 
in all six cancer types (Figure 7A), including head and 
neck squamous cell carcinoma (GSE6631), esophageal 
squamous cell carcinoma (GSE53624), breast cancer 
(GSE15852), lung adenocarcinoma (GSE12236), 
hepatocellular carcinoma (GSE14520), and colorectal 
carcinoma (GSE10950). In addition, by using the default 
thresholds set of p-value ≤ 10-4, 2-fold change and 10% 
Figure 4: Silencing of TNS2 enhances cancer cell tumorigenicity. A. Cell lysates from indicated cell lines were blotted with 
TNS2 or GAPDH antibodies. A549 or HeLa transfected with siRNA against TNS2 (siTNS2) or control (siCon) were analyzed by RT-
PCR assays with isoform specific primers B., blotted with TNS2 or GAPDH antibodies C., or analyzed for their 4-day growth rates by 
WST1 assays D. and their colony formation activities E. Numbers under RT-PCR gel panels (B)indicated band intensities comparing to 
corresponding siCon controls.
Figure 5: Silencing of TNS2 promotes tumor growth in xenograft models. shTNS2 and shLuc in HeLa cells were used for 
xenograft assay in NSG mice. Down-regulation of TNS2 protein level in shTNS2 was confirmed by western blot analysis (left panel). 
Tumors are pictured (middle panel) along with the measured average size (right panel). * P-value <0.05
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top gene rank, 31 out of a total of 415 profiles in the 
Oncomine database showed significant TNS2 under-
expression (Figure 7B). These included bladder, brain, 
breast, cervical, colon, head and neck, kidney, liver, lung, 
ovarian cancers and sarcoma. Furthermore, using online 
survival analysis tools (PROGgeneV2 and Kaplan Meier-
plotter) [17–21], the correlation of low TNS2 expression 
with poor overall survival probability was analyzed in 
various cancer cohorts (Figure 7A). Although many 
databases did not show correlations, these were generally 
with smaller sample sizes. On the other hand, low 
expression of TNS2 was significantly associated with poor 
overall prognosis in seven lung cancer cohorts, two breast 
cancer cohorts and one bladder cancer group (Figure 8A). 
These groups usually had larger than 150 patients with 
more than 5 years follow up. In addition to the overall 
survival, patients’ relapse-free survival probabilities of 
TNS2 expression in 3 lung cancer datasets (GSE50081, 
GSE41271, and GSE31210) and 1 breast cancer dataset 
(GSE1456_U133A) were available and analyzed by using 
the online survival analysis tools at PROGgeneV2. One 
lung cancer (GSE3210) and one breast cancer (GSE1456_
U133A) datasets showed the significant correlation of 
low TNS2 expression with poor relapse-free survival 
(Figure 8B).
DISCUSSION
In this report, we have clarified the identities of 
three human TNS2 isoforms. Although it was previously 
described that only V1 and V2 contained the C1 domain 
[7, 15], our current studies strongly suggested that 
all three isoforms shared almost identical sequences, 
including the C1, PTP, SH2 and PTB domains. The only 
difference among these isoforms resides at their very 
N-terminal sequences. However, these sequence varieties 
do not lead to difference in terms of TNS2 protein 
subcellular localization. With the exception that V1 and 
V3 expressional profiles are different from that of V2, 
the biological significance of these sequence variations is 
currently not clear.
Our TNS2 knockdown experiments have indicated 
the role of TNS2 in suppressing tumorigenicity of cancer 
cells (Figure 5). However, it has been reported that 
Figure 6: Silencing of TNS2 activates IRS1, AKT, and Mek signaling networks. A. Cell lysates from A549 or HeLa transfected 
with siTNS2 or siCon were blotted with indicated antibodies. B. Cells treated with inhibitors to Mek (U0126), PI3K (LY294002), or DMSO 
were subjected to western blot analysis with antibodies against IRS1, P-IRS1(S616), or GAPDH.
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overexpression of TNS2 (KIAA form) promoted the 
tumorigenicity of BEL7402 and Hep3B [7]. On the other 
hand, overexpression of TNS2 V2 reduced BEL7402 
cancer cell colony formation activity [6]. No effect was 
observed with TNS2 overexpression in DU145 prostate 
cancer cells [15]. By analyzing human cancer expression 
profiles, we found TNS2 was down-regulated in a variety 
of cancers, including hepatocellular carcinoma (HCC) 
patients (Figure 7). For comparison, through Oncomine 
we applied the same thresholds for analysis of the 
expression of the tumor suppressor PTEN. In a total of 
449 profiles, PTEN was over-expressed in 3 profiles and 
under-expressed in 15 groups. These results indicated 
that under-expression of TNS2 was more common and 
Figure 7: TNS2 expression in human normal and tumor samples. A. Scatter plot of TNS2 expression values from expression 
profiles in six independent datasets: 22 pairs of normal and head and neck squamous cell carcinoma; 119 pairs of normal and esophageal 
squamous cell carcinoma; 43 pairs of normal and breast cancer samples; 20 pairs of normal and lung adenocarcinoma; 231 pairs of normal 
and hepatocellular carcinoma; and 32 pairs of normal and colorectal cancer. The statistical significances between normal (N) and tumor 
(T) samples were calculated with a two-tailed unpaired Student's t-test. P-values <0.05 were considered to be statistically significant. 
B. The expression between normal and various types of cancers was analyzed through Oncomine with default thresholds. The number 
of Oncomine profiles with significant TNS2 under-expression for each cancer-type is shown in the box under “Down”. All thirty-one 
significant cases showed TNS2 down-expression in cancer samples. None of 415 Oncomine profiles showed TNS2 up-regulation. The grey 
scales indicated TNS2 was on the top 1%, 5% or 10% altered genes. For example, TNS2 expression was among the top 5% genes that were 
the most down-regulated in 2 bladder cancer profiles in Oncomine.
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Figure 8: Overall survival analysis of cancer patients according to TNS2 expression levels. A. The correlation between 
TNS2 expression and patients’ overall survival probability. The patients’ survival probabilities of TNS2 expression in lung cancer (18 
datasets), breast cancer (7 datasets), kidney cancer (3 datasets), bladder cancer (4 datasets), head and neck cancer (1 dataset), brain cancer 
(8 datasets), and colorectal cancer (9 datasets) were analyzed by using the online survival analysis tools (PROGgeneV2 and Kaplan Meier-
plotter). P-values <0.05 are considered statistically significant. ns: not significant. B. Kaplan-Meier survival curve analyses were conducted 
in four larger datasets (N>150) with available disease relapse information. One lung cancer (GSE31210) and one breast cancer (GSE1456_
U133A) groups showed low TNS2 expression patients associated with poor relapse-free survival probabilities. The log rank p value, hazard 
ratio, lower and upper confidence intervals of hazard ratio retrieved from each cohort was displayed on the survival plot legend.
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consistent than PTEN in various cancer types. In addition, 
poor relapse-free survival rates were associated with 
patents with lower TNS2 levels in one lung and one breast 
cancer cohorts (Figure 8). These findings strongly support 
that experimental results obtained from silencing studies 
in cancer cells were more relevant to clinical conditions 
and that TNS2 overexpression in cancer patients probably 
is a very rare event. Nonetheless, it has been reported 
that the original V3 form (1285 aa with no C1 domain) 
was overexpressed in HCC tumor (in 50 pairs) and was 
associated with venous invasion (p = 0.037), tumor 
microsatellite formation (p = 0.033), and nonencapsulation 
(p = 0.049) [7]. Overexpression of GFP-V3 promoted 
liver cancer cell proliferation, migration, invasion, colony 
formation and orthotopic liver xenograft [7]. These 
findings suggest an oncogenic effect of TNS2 in HCC. The 
reasons for the discrepancy between their and our results 
are not clear and require further studies.
IRS1 (insulin receptor substrate 1) was originally 
identified as a critical substrate of the insulin receptor 
[22]. In the insulin signaling, IRS1 binds to and is 
tyrosine phosphorylated by activated insulin receptor. 
Phosphorylated IRS1 provides docking sites for numerous 
signaling molecules including Grb2, p85, Nck, Crk, and 
Fyn, which lead to activation of several downstream 
pathways, such as MAP kinase and PI3K pathways [23]. 
IRS1 also mediates signals to promote tumor progression. 
Overexpression of IRS1 in cells promoted cell 
transformation and in mice lead to tumor development [24, 
25]. Therefore, TNS2 may suppress cell transformation 
by regulating IRS1 protein and its activation levels. 
In the absence of TNS2, elevated IRS1 signaling may 
promote tumorigenicity in cancer cells. This is consistent 
with recent finding that TNS2 acts as a protein tyrosine 
phosphatase of IRS1 and dephosphorylation of pY612 of 
IRS1 by TNS2 accelerates IRS1 degradation [26]. Our 
studies further suggest that TNS2 may suppress IRS1 S616 
phosphorylation through regulating Mek and possibly also 
Akt activities. How TNS2 can negatively regulate Mek 
and Akt is under investigation.
MATERIALS AND METHODS
TNS2 cDNA expression plasmids
The 5’-end sequence of the TNS2 gene was amplified 
by using a commercially available 5’ Rapid Amplification 
of cDNA Ends (5’RACE) kit (Life Technologies) 
according to the manufacturer's instructions. Briefly, 
one reverse primer 105R (5’-TAGTACGACCACGTGC 
TGTGGGTCAG-3’) shared by all three isoforms was 
designed and subjected to a 5’RACE reaction using human 
control cDNA. The amplified fragments were subcloned 
into pCR2.1.TOPO (Invitrogen) and sequenced. On the 
basis of this sequence information, three non-identical 
clones were obtained. In order to construct the full length 
of the TNS2 cDNA isoforms, three different forward 
primers including an EcoRI site and the first ATG codon 
were designed as below:
V1: 5’-CGGAATTCATGGATGGGGGTGGAGTA
TG-3’
V2: 5’-CGGAATTCATGAAGTCCAGCGGCCC
TG-3’
V3: 5’-CGGAATTCATGTCCCTGGCGCGGCCC
GG-3’
PCR amplification was performed using each 
forward primer and the reverse primer 105R. The 
amplified DNA was subcloned into the EcoRI and PmlI 
sites of GFP-TNS2 (Chen et al., 2002) to generate 
pEGFPC2-TNS2V1, pEGFPC2-TNS2V2, and pEGFPC2-
TNS2V3. pTomato-TNS2V1 was generated by swapping 
EGFP with tdTomato using NheI and BsrGI sites.
Antibodies
Rabbit polyclonal anti-TNS2 KIAA was raised as 
described previously [4]. Anti-IRS1 (#3400), anti-pS616 
(mouse S612)-IRS1 (#3203), anti-Mek (#4694), anti-
pS217/221- Mek (#9154), anti-Erk (#4695), anti-pT202/
Y204-Erk (#4370) were purchased from Cell Signaling 
Technology. Anti-pY612-IRS1 (#09432) was from 
Millipore. And anti-GAPDH (#4300) was from Ambion. 
Akt-pS473 (# 7985) was from Santa Cruz Biotechnology.
Cell culture, siRNA transfection and lentiviral 
shRNA infection
HeLa and A549 cell lines were purchased from 
ATCC and cultured in Eagle's Minimum Essential 
Medium or Dulbecco’s modified Eagle’s medium 
(GIBCO) supplemented with 10 % FBS (Sigma) and 1% 
penicillin/streptomycin. TRC lentiviral shRNA targeting 
human TNS2 (TRCN0000272886) was obtained from the 
National RNAi Core Facility (Taiwan). The TNS2 targeting 
sequences are TCAGAGCCCACATCAACACTG for 
shRNA and CAGCAAAGAUCCUCUGGAA for siRNA.
RNA extraction and RT-qPCR
Total RNA was isolated using TriZol (Invitrogen) 
reagent per the manufacturer instructions. The cDNA 
was synthesized from total RNA using the High Capacity 
cDNA Reverse Transcription kit (Applied Biosystems). 
Real time PCR was performed using SYBR green master 
mix in a 7900HT Fast Real-Time PCR System (Applied 
Biosystems). Primers used for TNS2 quantitative PCR are 
listed below:
V1 (forward: 5’-GGGTGGAGTATGTGTTGGGA-3’; 
reverse: 5’-GAAAACCTTCTCCCGGAAGC-3’)
V2 (forward: 5’-ACACCATGAAGTCCAGCGG-3’; 
reverse: 5’-GAAAACCTTCTCCCGGAAGC-3’)
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V3 (forward: 5’-CTCTCTCCCCTCGGCTCTTT-3’; 
reverse: 5’-GAAAACCTTCTCCCGGAAGC-3’)
The relative expressions levels of TNS2 in the 
tissues are shown following normalization with β-actin 
transcript values.
Western blotting
Cultured cells were lysed with RIPA buffer (50 
mM Tris Cl, pH 7.4/150 mM NaCl/5 mM EDTA/1% 
Nonidet P-40/1% sodium deoxycholate/0.1% SDS) with 
protease and phosphatase inhibitors (Roche). The protein 
concentration was determined using the BioRad protein 
assay Kit (BioRad). Lysates were separated in a 7-15 % 
sodium dodecyl sulfate–polyacrylamide electrophoresis 
(SDS-PAGE) gel, transferred to nitrocellulose membranes, 
and incubated with indicated antibodies and visualized by 
enhanced chemiluminescence (ECL).
Immunofluorescence and confocal microscopy
Cells cultured on acid-treated coverslips were 
fixed with 4 % paraformaldehyde/PBS for 15 min and 
subsequently permeabilized with 0.1 % Triton X-100/
PBS for 5 min. After blocking with 5 % goat serum, the 
cells were incubated with primary antibodies, anti-vinculin 
(1:200) followed by appropriate secondary antibodies 
conjugated with Alexa Flour (Invitrogen). The coverslips 
were mounted on slides using DAPI-containing mounting 
solution (Vector Laboratories) and digital images were 
acquired with a Zeiss LSM 710 confocal system.
Proliferation and colony formation assays
Cells were transfected with control siRNA or TNS2 
siRNA (sigma) using Lipofectamine 2000 (Invitrogen). 
After 48h, 10,000 cells were seeded into a 48 well plate 
and cultured for 4 days. The growth of cells was measured 
using the WST1 cell proliferation assay system (Roche) 
according to manufacturer instructions. For colony 
formation assay, cells were co-transfected with EGFPC2 
plasmid and control siRNA or TNS2 siRNA. After 48h, 
5,000 cells were seeded and selected by 400 ug/ml 
Geneticin (Invitrogen) in a 6 well plate. After 2 weeks 
of selection, colonies were fixed with formaldehyde and 
stained with crystal violet.
Xenograft models
Cells (2 × 106) were suspended in 200 μL of 50 % 
matrigel in PBS and injected subcutaneously into the both 
flanks of NSG mice. After 4 weeks, mice were killed, 
and tumors removed for analysis. Tumor diameters were 
measured with digital calipers, and the tumor volume in 
mm3 was calculated by the formula, volume = (width)2 
x length/2. All animal procedures were approved by the 
Institutional Animal Care and Use Committee (IACUC) 
at the University of California Davis.
Microarray database analyses
The expression between normal and various types 
of cancers was analyzed by Oncomine. Default threshold 
p-value ≤ 10-4, 2-fold change, and 10% gene rank set 
was used to generate the disease summary of TNS2. 
Gene expression data from Gene Expression Omnibus 
(GEO) database NCBI was downloaded to analyze the 
TNS2 expression in normal and cancer paired samples. 
Selection criteria for all publicly available datasets 
required each dataset to include normal and cancer paired 
samples for more than twenty patients. Six microarray 
datasets containing the normal and tumor pair samples 
were selected from the NCBI GEO database, including 
GSE6631 (22 pairs of head and neck squamous cell 
carcinoma), GSE53624 (119 pairs of esophageal squamous 
cell carcinoma), GSE15852 (43 pairs of breast cancer), 
GSE12236 (20 pairs of lung adenocarcinoma), GSE14520 
(231 pairs of hepatocellular carcinoma), and GSE10950 
(32 pairs of colorectal cancer). Significantly expressed 
TNS2 gene is determined based on the comparison of 
the normal and tumor data. Scattered plot of TNS2 gene 
expression value (y-axis) for each cancer subtype was 
generated by GraphPad Prism 5. The patients’ survival 
probabilities of TNS2 expression in various cancers 
were analyzed by using the online survival analysis 
tools and datasets at www.watson.compbio.iupul.edu for 
PROGgeneV2 and www.kmplot.com for Kaplan Meier-
plotter. Each cohort was divided into two subgroups based 
on median expression of TNS2 to analyze the correlation 
between TNS2 expression and overall survival. The 
Kaplan-Meier plots, log rank p value, hazard ratio, lower 
and upper confidence intervals of hazard ratio displayed 
on the survival plot legend were also generated using these 
online tools.
Statistical analysis
Statistical analysis was performed using the using 
GraphPad Prism 5. All results are expressed as mean ± 
SD. Significance was defined as p £0.05.
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